Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2021 | Nab-paclitaxel-based induction therapy, chemotherapy and re-irradiation for head and neck cancer

Ari Rosenberg, MD, University of Chicago Medical Center, Chicago, IL, discusses the Phase I trial (NCT01847326) of nab-paclitaxel-based induction therapy followed by nab-paclitaxel-based chemotherapy and re-irradiation for patients with previously-treated head and neck cancer. The primary endpoints were maximum dosage and dose-limiting toxicity of nab-paclitaxel when combined with the FHX regimen (5-fluorouracil, hydroxyurea, and twice-daily radiation). Secondary endpoints were progression-free survival (PFS) and overall survival (OS). The recommended Phase II dosage was determined to be 100mg/m2. 23% of patients saw a 4-year PFS and 26% achieved OS. The PFS and OS rates were higher in patients responding to induction chemotherapy and were then treated with chemo-irradiation. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.